Repeated Vaccination at the Same Skin Site Creates a Powerful Anti-Tumor Immune Environment | Research

The takeaway

Repeated peptide vaccination at the same skin site with IFA adjuvant created a strongly Th1-dominant, anti-tumor microenvironment with activated immune cells and reduced immunosuppression in melanoma patients.

p<0.0001 for CD40/CD40L
Same-site peptide vaccination dramatically increased immune activation markers at the injection site

What the researchers found

Same-site vaccination (SSV×3) with peptides in IFA dramatically enhanced Th1 markers (TBX21, IFNγ, STAT1), reduced immunosuppressive ARG1, increased TLR adapter expression, and promoted tertiary lymphoid structure formation at the vaccine site.

Why it matters

Understanding how adjuvants and vaccination schedules shape the local immune environment can help optimize cancer vaccine strategies for stronger anti-tumor responses.

The numbers in context

27 patients; CD40/CD40L p<0.0001; SSV×3 enhanced TBX21, IFN-γ, STAT1; decreased GATA3 and ARG1

How the study worked

Clinical observational study with VSME biopsies from 27 melanoma patients across two clinical trials (NCT00705640, NCT01585350). RNAseq gene expression analysis comparing single vaccination, repeated same-site vaccination, and controls (normal skin, IFA-only).

Who was studied

Melanoma patients enrolled in two clinical trials (NCT00705640, NCT01585350)

What this study cannot tell us

Observational biopsy study — no direct tumor outcome data. Small sample size (n=27). Only melanoma patients studied. Gene expression does not always correlate with functional immune responses.

How to read the evidence

Preliminary — human biopsy data from clinical trials but observational in nature with a small sample and no direct clinical outcome measurements.

When this study was published

Published in 2020; findings from two registered clinical trials continue to inform cancer vaccine scheduling strategies.

The bigger picture

This study provides mechanistic evidence that vaccination strategy — not just vaccine composition — critically shapes immune outcomes. The finding that same-site vaccination creates tertiary lymphoid structures could influence cancer immunotherapy protocols broadly.

Questions still open

Does the enhanced local immune environment from SSV translate to better clinical outcomes in melanoma patients?
Would same-site vaccination with other adjuvants produce similar tertiary lymphoid structures?
Can the skin microbiome effects suggested by TLR adapter upregulation be harnessed to improve vaccine responses?

Common questions

Why vaccinate at the same spot repeatedly?

Repeated vaccination at one site concentrates immune responses locally, creating lymph node-like structures that amplify the anti-tumor immune response. This approach appears more effective than rotating injection sites.

What is a Th1-dominant environment and why does it matter for cancer?

Th1 refers to a type of immune response that activates killer cells and inflammation — exactly what you want for fighting tumors. A Th1-dominant vaccine site means the immune system is being steered toward cancer-fighting mode rather than tolerance.

Read the original research

Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.

Journal for immunotherapy of cancer, 8(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Pollack, Karlyn E; Meneveau, Max O; Melssen, Marit M; Lynch, Kevin T; Koeppel, Alexander F; Young, Samuel J; Turner, Stephen; Kumar, Pankaj; Sol-Church, Katia; Mauldin, Ileana S; Slingluff, Craig L. (2020). Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.. Journal for immunotherapy of cancer, 8(1). https://doi.org/10.1136/jitc-2020-000544